论文部分内容阅读
药品集中招标采购作为一项重要的国家药品政策(NMP),对制药企业的影响是巨大的。如果制药企业的产品中标品种多、中标范围广,这就预示着制药企业将获得更大的市场份额和更广阔的发展空间。否则,企业将难以维计生存,更谈不上发展。因而,一个药厂的产品能否在某个地区中标,直接关系到药厂在该地区的销售业绩和市场份额,在某种程度上关系到药厂的生存与发展。
Centralized drug bidding As an important national pharmaceutical policy (NMP), the impact on pharmaceutical companies is enormous. If the pharmaceutical companies bid more varieties of products, winning a wide range, which indicates that pharmaceutical companies will gain greater market share and broader space for development. Otherwise, enterprises will find it hard to make a living, let alone development. Therefore, whether a pharmaceutical product can win a bid in a certain region is directly related to the pharmaceutical sales in the region and market share, to some extent, the survival and development of pharmaceutical companies.